NCT00576589View on ClinicalTrials.gov

Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 31, 2008

Study Completion Date

September 30, 2008

Conditions
Obesity
Interventions
DRUG

CE-326,597

CE-326,597 administered orally, once daily for 14-days at 1 to 2 doses (25 mg QD, 100 mg QD) with the morning meal.

DRUG

Placebo

CE-326,597 matching placebo administered orally, once daily for 14-days with the morning meal.

Trial Locations (12)

32720

Pfizer Investigational Site, DeLand

32809

Pfizer Investigational Site, Orlando

33143

Pfizer Investigational Site, Miami

Pfizer Investigational Site, South Miami

36201

Pfizer Investigational Site, Anniston

36207

Pfizer Investigational Site, Anniston

42431

Pfizer Investigational Site, Madisonville

67214

Pfizer Investigational Site, Wichita

85013

Pfizer Investigational Site, Phoenix

92801

Pfizer Investigational Site, Anaheim

96813

Pfizer Investigational Site, Honolulu

08046

Pfizer Investigational Site, Willingboro

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY